Roivant Sciences | search
Click here to view Roivant Sciences news from 60+ newspapers.
Bookmark or Share- Company Overview | Roivant - Roivant SciencesRoivant builds nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Our Vants have conducted 10 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults.
- Roivant Sciences - WikipediaRoivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. [3]
- Roivant Sciences Ltd. (ROIV) - Yahoo FinanceFind the latest Roivant Sciences Ltd. (ROIV) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Roivant Reports Financial Results for the Second Quarter - GlobeNewswireROIVANT SCIENCES LTD. Selected Balance Sheet Data (unaudited, in thousands) September 30, 2024 March 31, 2024 Cash, cash equivalents and restricted cash
- Roivant Sciences Ltd (ROIV) Q2 2024 Earnings Call Highlights: Strong ...Roivant Sciences Ltd (NASDAQ:ROIV) has a strong financial position with $5.4 billion in cash and no debt following the Dermavant transaction. The company has repurchased $754 million worth of ...
More
